Biomarin Pharmaceutical Inc (LTS:0HNC)
$ 76.46 -0.06 (-0.08%) Market Cap: 14.69 Bil Enterprise Value: 14.74 Bil PE Ratio: 72.28 PB Ratio: 2.89 GF Score: 71/100

Biomarin Pharmaceutical Inc at UBS Global Healthcare Virtual Conference Transcript

May 24, 2021 / 03:00PM GMT
Release Date Price: $78.44 (+0.55%)
Colin Nigel Bristow
UBS Investment Bank, Research Division - Analyst

Good morning, and thank you, everyone, for joining the virtual UBS Global Healthcare Conference. So I'm Colin Bristow, one of the biotech analysts here. And it's my pleasure to have BioMarin here with me today. So speaking on behalf of the company, we have J.J. Bienaime, CEO of BioMarin; and Brian Mueller, CFO of BioMarin. So J.J., Brian, thank you for joining us today. Before we start, if anyone has a question, there is like a raise your hand function within this video system. But alternatively, feel free to e-mail me directly at [email protected], and I can try and field the question for you. So J.J., good morning. Congrats on the EMA accelerated assessment for Valrox, that was great timing. Thanks for organizing that for us. And I know you have some remarks. So right now, I'll hand it over to you. J.J.?

Jean;Jacques Bienaime
BioMarin Pharmaceutical Inc. - Chairman & CEO

Thank you, Colin. We appreciate the opportunity to speak with you today. As you said, this

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot